Loading...

Organogenesis Holdings

Nasdaq:ORGO
Snowflake Description

Concerning outlook with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ORGO
Nasdaq
$647M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The last earnings update was 13 days ago. More info.


Add to Portfolio Compare Print
  • Organogenesis Holdings has significant price volatility in the past 3 months.
ORGO Share Price and Events
7 Day Returns
1.3%
NasdaqCM:ORGO
1%
US Biotechs
0.2%
US Market
1 Year Returns
-
NasdaqCM:ORGO
-4.6%
US Biotechs
2.9%
US Market
ORGO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Organogenesis Holdings (ORGO) 1.3% -0.7% -9.7% - - -
US Biotechs 1% -0% -3.2% -4.6% 3.8% 9.7%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • No trading data on ORGO.
  • No trading data on ORGO.
Price Volatility
Industry
5yr Volatility vs Market

ORGO Value

 Is Organogenesis Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Organogenesis Holdings. This is due to cash flow or dividend data being unavailable. The share price is $7.08.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Organogenesis Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Organogenesis Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:ORGO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.76
NasdaqCM:ORGO Share Price ** NasdaqCM (2019-05-22) in USD $7.08
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Organogenesis Holdings.

NasdaqCM:ORGO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ORGO Share Price ÷ EPS (both in USD)

= 7.08 ÷ -0.76

-9.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Organogenesis Holdings is loss making, we can't compare its value to the US Biotechs industry average.
  • Organogenesis Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Organogenesis Holdings's expected growth come at a high price?
Raw Data
NasdaqCM:ORGO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
22.3%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.26x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Organogenesis Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Organogenesis Holdings's assets?
Raw Data
NasdaqCM:ORGO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.36
NasdaqCM:ORGO Share Price * NasdaqCM (2019-05-22) in USD $7.08
United States of America Biotechs Industry PB Ratio Median Figure of 414 Publicly-Listed Biotechs Companies 3.35x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
NasdaqCM:ORGO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ORGO Share Price ÷ Book Value per Share (both in USD)

= 7.08 ÷ 0.36

19.86x

* Primary Listing of Organogenesis Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Organogenesis Holdings is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Organogenesis Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Organogenesis Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ORGO Future Performance

 How is Organogenesis Holdings expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Organogenesis Holdings expected to grow at an attractive rate?
  • Unable to compare Organogenesis Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Organogenesis Holdings's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Organogenesis Holdings's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:ORGO Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:ORGO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 22.3%
NasdaqCM:ORGO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 8%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:ORGO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:ORGO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 360 -9 -8 1
2022-12-31 310 -21 -21 3
2021-12-31 272 -29 -40 3
2020-12-31 273 -16 -33 3
2019-12-31 255 -27 -40 3
NasdaqCM:ORGO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 215 -66 -58
2018-12-31 193 -61 -65
2018-09-30 183 -46 -60
2018-06-30 184 -25 -52
2018-03-31 187 -9 -32
2017-12-31 199 -4 -9
2016-12-31 139 -5 -17

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Organogenesis Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Organogenesis Holdings's revenue is expected to grow by 8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:ORGO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Organogenesis Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:ORGO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.08 -0.08 -0.08 1.00
2022-12-31 -0.22 -0.20 -0.27 3.00
2021-12-31 -0.44 -0.39 -0.47 3.00
2020-12-31 -0.36 -0.26 -0.43 3.00
2019-12-31 -0.44 -0.35 -0.50 3.00
NasdaqCM:ORGO Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.76
2018-12-31 -0.94
2018-09-30 -1.84
2018-06-30 -1.64
2018-03-31 -0.44
2017-12-31 -0.14
2016-12-31 -0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Organogenesis Holdings will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Organogenesis Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Organogenesis Holdings has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ORGO Past Performance

  How has Organogenesis Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Organogenesis Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Organogenesis Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Organogenesis Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Organogenesis Holdings's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Organogenesis Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Organogenesis Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:ORGO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 215.04 -58.01 168.44 11.29
2018-12-31 193.45 -64.83 158.30 10.74
2018-09-30 182.99 -60.00 151.87 10.39
2018-06-30 183.68 -52.32 148.66 9.93
2018-03-31 187.08 -31.80 141.80 9.89
2017-12-31 198.51 -8.81 133.93 9.07
2016-12-31 138.73 -16.99 93.03 6.28
2015-12-31 98.98 -24.26 74.22 3.88

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Organogenesis Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Organogenesis Holdings has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Organogenesis Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Organogenesis Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Organogenesis Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ORGO Health

 How is Organogenesis Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Organogenesis Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Organogenesis Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Organogenesis Holdings's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Organogenesis Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Organogenesis Holdings Company Filings, last reported 1 month ago.

NasdaqCM:ORGO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 32.56 88.07 30.56
2018-12-31 47.04 59.26 21.29
2018-09-30 -24.23 127.73 25.77
2018-06-30 -57.17 124.05 1.26
2018-03-31 -15.32 106.84 2.31
2017-12-31 -15.32 106.84 2.31
2016-12-31 -15.98 87.89 1.69
2015-12-31
  • Organogenesis Holdings's level of debt (270.5%) compared to net worth is high (greater than 40%).
  • Unable to establish if Organogenesis Holdings's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Organogenesis Holdings has less than a year of cash runway based on current free cash flow.
  • Organogenesis Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 94.6% each year.
X
Financial health checks
We assess Organogenesis Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Organogenesis Holdings has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ORGO Dividends

 What is Organogenesis Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Organogenesis Holdings dividends. Estimated to be 0% next year.
If you bought $2,000 of Organogenesis Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Organogenesis Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Organogenesis Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:ORGO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:ORGO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Organogenesis Holdings has not reported any payouts.
  • Unable to verify if Organogenesis Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Organogenesis Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Organogenesis Holdings has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Organogenesis Holdings's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Organogenesis Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Organogenesis Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Organogenesis Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ORGO Management

 What is the CEO of Organogenesis Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gary Gillheeney
COMPENSATION $3,158,313
AGE 63
TENURE AS CEO 5.3 years
CEO Bio

Mr. Gary S. Gillheeney, Sr. serves as the Chief Executive Officer and President of Organogenesis Inc., since 2014 and has been its Director since December 10, 2018. Mr. Gillheeney served as Organogenesis's Executive Vice President, Chief Operating Officer and Chief Financial Officer from 2003 to 2014 and also Chief Financial Officer from 2002 to 2003. Prior to joining Organogenesis, Mr. Gillheeney held executive positions at Innovative Clinical Solutions, Ltd., a provider of decision support and clinical knowledge solutions to healthcare staff, from 1999 to 2002, as its Chief Operating Officer, Chief Financial Officer, as well as Treasurer and Secretary. Prior to joining Innovative Clinical Solutions, Mr. Gillheeney held positions as Senior Vice President, Chief Financial Officer, Treasurer, and Assistant Secretary at Providence Energy Corporation. Mr. Gillheeney has a B.S. in Accounting from American International College and an M.B.A. from Bryant College.

CEO Compensation
  • Gary's compensation has increased whilst company is loss making.
  • Gary's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Organogenesis Holdings management team in years:

2.3
Average Tenure
53.5
Average Age
  • The tenure for the Organogenesis Holdings management team is about average.
Management Team

Gary Gillheeney

TITLE
President
COMPENSATION
$3M
AGE
63
TENURE
5.3 yrs

Lori Freedman

TITLE
VP & General Counsel
COMPENSATION
$595K
AGE
51
TENURE
2.3 yrs

Howard Walthall

TITLE
Executive Vice President of Strategy & Market Development
COMPENSATION
$572K
AGE
46
TENURE
2.3 yrs

Tim Cunningham

TITLE
Chief Financial Officer
AGE
56
TENURE
2.7 yrs

Patrick Bilbo

TITLE
Chief Operating Officer
AGE
56
TENURE
1.7 yrs

Angelyn Lowe

TITLE
Director of Corporate Communications

Thomas Pearl

TITLE
Vice President of Human Resources
TENURE
0.9 yrs

Zorina Pitkin

TITLE
Senior Vice President of Quality Systems
TENURE
11.3 yrs

Brian Grow

TITLE
Chief Commercial Officer
AGE
42
TENURE
1.7 yrs
Board of Directors Tenure

Average tenure and age of the Organogenesis Holdings board of directors in years:

0.4
Average Tenure
63.5
Average Age
  • The average tenure for the Organogenesis Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Alan Ades

TITLE
Chairman of the Board
AGE
79

Gary Gillheeney

TITLE
President
COMPENSATION
$3M
AGE
63
TENURE
0.4 yrs

Arthur Leibowitz

TITLE
Director
COMPENSATION
$85K
AGE
64
TENURE
0.4 yrs

Wayne Mackie

TITLE
Director
COMPENSATION
$84K
AGE
69
TENURE
0.4 yrs

Albert Erani

TITLE
Director
AGE
77
TENURE
0.4 yrs

Glenn Nussdorf

TITLE
Director
AGE
63
TENURE
0.4 yrs

Joshua Tamaroff

TITLE
Director
COMPENSATION
$84K
AGE
32
TENURE
0.4 yrs

Maurice Ades

TITLE
Director
AGE
50
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Organogenesis Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Organogenesis Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ORGO News

Simply Wall St News

ORGO Company Info

Description

Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company’s advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company’s pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Details
Name: Organogenesis Holdings Inc.
ORGO
Exchange: NasdaqCM
Founded: 1985
$646,517,556
91,316,039
Website: http://organogenesis.com
Address: Organogenesis Holdings Inc.
85 Dan Road,
Canton,
Massachusetts, 02021,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ORGO Class A Common Stock Nasdaq Capital Market US USD 08. Jan 2019
DB 2PQ Class A Common Stock Deutsche Boerse AG DE EUR 08. Jan 2019
Number of employees
Current staff
Staff numbers
700
Organogenesis Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 06:50
End of day share price update: 2019/05/22 00:00
Last estimates confirmation: 2019/05/15
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.